Open AccessKajian Mutu Produk Tablet Metformin Hidroklorida Extended-Release yang Dipasarkan di Indonesia
Author(s) -
Yuni Anggraeni,
Umniyaty Mufidah,
Muhammad Umar
Publication year - 2022
Publication title -
pharmaceutical and biomedical sciences journal (online)/pharmaceutical and biomedical sciences journal
Language(s) - English
Resource type - Journals
eISSN - 2715-6702
pISSN - 2715-2979
DOI - 10.15408/pbsj.v3i2.24755
Subject(s) - metformin hydrochloride , immediate release , mathematics , dissolution , dissolution testing , chemistry , chromatography , medicine , metformin , organic chemistry , biopharmaceutics classification system , endocrinology , diabetes mellitus
Some metformin hydrochloride extended-release (MetHCl-XR) tablet products have been marketed in Indonesia with varying prices. In general, price is considered to indicates the quality of a product. This research was conducted to review the products quality, especially the dissolution rate of the products, and to find out if the price is an indicator of the product quality. Three brands of MetHCl 500 mg XR tablets were randomly selected, namely Tablet A, B, and C which the price of Tablet B > A > C, then the Tablets were characterized. The results showed that Tablet A, B, and C contain MetHCl with an average of 100.61%, 98.72%, and 101.15% respectively, and met the uniformity of dosage unit requirement. Tablet A met the requirements of dissolution tests 1, 2, 3, and 4, while Tablet B and C met the requirements of dissolution tests 1 and 3. The cumulative percentage of MetHCl release at the 10th hour of Tablet A, B, and C were 94.18%, 97.24%, and 94.59% respectively with the release kinetics of Tablet A and B following Higuchi model, whereas Tablet C following a first-order. Drug release of all tablets occurred in non-Fick diffusion. In conclusion, the three tablets met the standards required by USP 43 and the price is not an indicator of MetHCl-XR tablet products quality.